Endocrinology | Home | MIMS Malaysia

Malaysia
Search
Sign In

Endocrinology Search

Endocrinology

Endocrinology

Home News Diseases Conferences Special Reports Multimedia

Cholesterol metabolism heightened in liver, brain of citrin-deficient children

Yesterday

Citrin-deficient children have increased high-density lipoprotein cholesterol (HDL-C) and sterol marker concentrations after neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD), according to a study. In addition, these children have significantly enhanced cholesterol synthesis and elimination in the liver and brain.

Self-efficacy enhancing programmes improve glycaemic control in diabetics

Tristan Manalac, Yesterday

Diabetes self-efficacy enhancing programmes (DSEEPs) help improve diabetes self-care activities and glycaemic control in older adults with type 2 diabetes mellitus (T2DM), according to a recent Singapore study.

Metformin shows anti-TB effect in patients with type 2 diabetes

Jairia Dela Cruz, Yesterday

Treatment with metformin appears to significantly reduce tuberculosis (TB) risk in patients with type 2 diabetes mellitus, a study has found. However, this protective effect diminishes with age and is absent among those with metabolic disorders.

NIH, IMU collaboration to boost research, have health impact on Malaysians

Saras Ramiya, 4 days ago

The National Institutes of Health (NIH) and International Medical University (IMU) strengthens their research collaboration with the recent signing of a Memorandum of Understanding (MoU).

Reproductive history may influence dementia, Alzheimer’s risk

Roshini Claire Anthony, 6 days ago

Fewer children, older age at menarche, and a higher number of miscarriages are among factors that may raise a woman’s risk of dementia, according to a study presented at the recent Alzheimer’s Association International Conference (AAIC 2018).

Redefining diabetes management: Combining glycaemic control with cardiovascular protection to deliver better patient outcomes

31 May 2018

At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.

Optimizing hormone replacement therapy in menopause

05 Apr 2017

At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.

The Future of Osteoporosis Management

20 Jan 2017

At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.

Role of gliclazide MR today: Efficacy and safety you can trust

04 Jan 2017

At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).

Preventing 3 key heart failure risk factors in midlife may prolong disease-free survival

Pearl Toh, 07 Dec 2016

Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.

Dual-hormone artificial pancreas beats insulin-alone system in glycaemic control in small study

Pearl Toh, 10 Jul 2018

A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.

Sotagliflozin sustains HbA1c reductions, improves outcomes over 1 year in T1D

Roshini Claire Anthony, 10 Jul 2018

Combining the dual sodium glucose cotransporter (SGLT) 1 and 2 inhibitor sotagliflozin with optimized insulin therapy led to sustained reductions in HbA_1c levels over 1 year in adults with type 1 diabetes (T1D), according to a study presented at ADA 2018.

Exenatide-dapagliflozin efficacy for T2D persists for 2 years

Elvira Manzano, 06 Jul 2018

Combined treatment with the GLP-1 receptor agonist exenatide and the SGLT-2 inhibitor dapagliflozin appeared to be effective up to 2 years in patients with type 2 diabetes (T2D), the phase III DURATION-8 extension trial has shown.

No increased risk of below-knee amputation with canagliflozin

Roshini Claire Anthony, 05 Jul 2018

The sodium glucose co-transporter 2 (SGLT-2) inhibitor canagliflozin does not appear to increase the risk of below-knee lower extremity amputations over other SGLT2 inhibitors or non-SGLT2 inhibitor antihyperglycaemic agents in patients with type 2 diabetes (T2D), but may reduce the risk of hospitalization for heart failure (HHF), according to findings of the US-based OBSERVE-4D* study.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!